Skip to main content

Table 4 Clinical outcomes by the selected studies

From: Oligometastasis and local ablation in the era of systemic targeted and immunotherapy

Authors

(year of publication) [reference]

Local Control

Distant progression free survival

Overall Survival

Toxicity

Weickhardt et al. (2012) [29]

N.S.

6.2 months

N.S.

2 ≥ G3

Iyengar et al. (2014) [23]

N.S.

14.7 months

20.4 months

2 > G3

Borghetti et al. (2019) [25]

N.S.

N.S.

23 months

0 > G3

Qiu et al. (2017) [24]

81.4%

7 months

35 months

2 > G3

Rossi et al. (2019) [26]

N.S.

13.8 months

35 months

N.S.

Weiss et al. (2019) [30]

N.S.

6 months

29 months

N.S.

Chan OSH et al. (2018) [31]

N.S.

15 months

N.S.

0 > G3

Xu et al. (2018) [27]

N.S.

20.6 months

40.9 months

14% > G3